Inquire Before Buying
Speak to an Analyst
Request Brochure
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
Read More- Home
- |
- Press Release
- |
- Biosimilar Market in Europe
Biosimilar Market in Europe to Reach US$ 53,222.9 Million by 2032, Impelled by Development of Strict Regulatory Guidelines for Biosimilar Review
January 06, 2022
| Healthcare
According to the latest report by IMARC Group, titled "Biosimilar Market in Europe Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Country 2024-2032," the biosimilar market in Europe reached a value of US$ 11,849.5 Million in 2023. Biosimilars are medical products that are generally manufactured from biological substances, such as microorganisms and animal or plant cells. They are extensively used in the production of vaccines, therapeutic proteins and monoclonal antibodies. Additionally, they are utilized by healthcare professionals for preventing, determining, and treating numerous medical ailments. These products are usually produced under the guidance of licensed facilities that are tracked as an essential part of post-market surveillance. They are considered to be harmless and safe for medical use with minor differences in clinically inactive components.
Europe Biosimilar Market Trends:
The market in Europe is primarily driven by the rising prevalence of chronic illnesses due to the sedentary lifestyle patterns of the masses. Additionally, the multiple initiatives undertaken by the governments of numerous countries towards the development of a comprehensive set of stringent regulatory guidelines for biosimilar review are positively influencing the market growth across the region. Furthermore, increasing investments and funding by private and public agencies to upgrade the existing healthcare infrastructure and various technological advancements across the sector are considered to be major growth-inducing factors. Other factors, including the rising awareness regarding the availability of biosimilars among patients, patent expiration of numerous blockbuster biologics and extensive research and development (R&D) activities conducted by key players in biotechnology and medical science, are further projected to drive the market growth across Europe. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 53,222.9 Million by 2032.
Market Summary:
- Based on the molecule, the market has been segmented into infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, follitropin alfa and adalimumab.
- On the basis of the indication, the market has been classified into auto-immune diseases, blood disorders, diabetes, oncology, growth deficiency and female infertility.
- Based on the manufacturing type, the market has been bifurcated into in-house manufacturing and contract manufacturing.
- On the basis of the country, the market has been divided into Italy, Germany, the United Kingdom, France, Spain and the rest of Europe.
- The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of these players include Novartis, Pfizer, Teva, Celltrion, Samsung Bioepis, Amgen, Apotex, Ratiopharm, Mylan, Merck Sharp & Dohme, Eli Lilly, Accord Healthcare Ltd, Boehringer Ingelheim, Hexal Ag and Stada Arzneimittel Ag.
Report Scope:
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Units | US$ Million |
| Segment Coverage | Molecule, Indication, Manufacturing Type, Country |
| Countries Covered | Italy, Germany, United Kingdom, France, Spain, Rest of Europe |
| Companies Covered | Novartis, Pfizer, Teva, Celltrion, Samsung Bioepis, Amgen, Apotex, Ratiopharm, Mylan, Merck Sharp & Dohme, Eli Lilly, Accord Healthcare Ltd, Boehringer Ingelheim, Hexal Ag, and Stada Arzneimittel Ag |
| Customization Scope | 10% Free Customization |
| Report Price and Purchase Option | Single User License: US$ 3699 Five User License: US$ 4699 Corporate License: US$ 5699 |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas: - +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Purchase options
Benefits of Customization
Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
Read More
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
Read More
Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
Read More.webp)
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
Read More
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
Read More
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
Read More
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
Read More
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
Read More.webp){kind=logo}
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
Read More
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
Read More